Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Belite Bio, Inc, a clinical-stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting atrophic age-related macular degeneration and autosomal recessive stargardt diseases. Its lead product candidate is LBS-008, an oral once-a-day treatment that can reduce and maintain the delivery of vitamin A to the eye to reduce the accumulation of toxic vitamin A by-products in ocular tissue that is in phase 3 clinical trial. The company is also developing LBS-009, an anti-retinol binding protein 4 oral therapy targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes, which is in the preclinical development phase. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc operates as a subsidiary of Lin Bioscience International Ltd.

Belite Bio, Inc

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

TINLAREBANT IS THE FIRST THERAPEUTIC CANDIDATE TO DEMONSTRATE CLINICAL EFFICACY IN STARGARDT DISEASE TYPE 1, HAVING MET THE PRIMARY EFFICACY ENDPOINT, REDUCTION IN LESION GROWTH PRESENTATION TO INCLUDE POSITIVE UPDATE ON SECONDARY ENDPOINTS, WITH QUANTITATIVE AUTOFLUORESCENCE SHOWING A MARKED DIVERGENCE BETWEEN TREATMENT GROUPS NEW DRUG APPLICATION TO THE U.S. FOOD AND DRUG ADMINISTRATION FOR TINLAREBANT COMPLETED SAN DIEGO, JULY 20, 2026 (GLOBE NEWSWIRE) -- BELITE BIO, INC (NASDAQ: BLTE) (BELITE BIO OR THE COMPANY), A CLINICAL-STAGE DRUG DEVELOPMENT COMPANY FOCUSED ON ADVANCING NOVEL THERAPEUTICS TARGETING DEGENERATIVE RETINAL DISEASES THAT HAVE SIGNIFICANT UNMET MEDICAL NEEDS, TODAY ANNOUNCED ADDITIONAL, POSITIVE SECONDARY ENDPOINT DATA FROM ITS PHASE 3 DRAGON TRIAL OF TINLAREBANT IN STARGARDT DISEASE TYPE 1 (STGD1). THE FINDINGS, ALONG WITH PREVIOUSLY REPORTED TOPLINE DATA, WERE DELIVERED IN AN ORAL PRESENTATION AT THE AMERICAN SOCIETY OF RETINA SPECIALISTS (ASRS) 2026 ANNUAL MEETING ON JULY 18, 2026, IN MONTRAL, CANADA.

BELITE BIO ANNOUNCES ORAL PRESENTATION AT THE ASRS ANNUAL MEETING FEATURING ADDITIONAL POSITIVE SECONDARY ENDPOINT DATA FROM THE PHASE 3 TRIAL OF TINLAREBANT IN STARGARDT DISEASE TYPE 1

SAN DIEGO, JULY 15, 2026 (GLOBE NEWSWIRE) -- BELITE BIO, INC (NASDAQ: BLTE) (BELITE BIO OR THE COMPANY), A CLINICAL-STAGE DRUG DEVELOPMENT COMPANY FOCUSED ON ADVANCING NOVEL THERAPEUTICS TARGETING DEGENERATIVE RETINAL DISEASES THAT HAVE SIGNIFICANT UNMET MEDICAL NEEDS, TODAY ANNOUNCED THAT THE COMPANY WILL PARTICIPATE IN A PANEL DISCUSSION AT THE H.C. WAINWRIGHT 6TH ANNUAL OPHTHALMOLOGY VIRTUAL CONFERENCE ON WEDNESDAY, JULY 22, 2026, AT 3:00 PM ET.

BELITE BIO TO PARTICIPATE IN THE H.C. WAINWRIGHT 6TH ANNUAL OPHTHALMOLOGY VIRTUAL CONFERENCE

SAN DIEGO, JULY 06, 2026 (GLOBE NEWSWIRE) -- BELITE BIO, INC (NASDAQ: BLTE) (BELITE BIO OR THE COMPANY), A CLINICAL-STAGE DRUG DEVELOPMENT COMPANY FOCUSED ON ADVANCING NOVEL THERAPEUTICS TARGETING DEGENERATIVE RETINAL DISEASES THAT HAVE SIGNIFICANT UNMET MEDICAL NEEDS, TODAY ANNOUNCED THAT THE COMPANY WILL PARTICIPATE IN A FIRESIDE CHAT AT THE PIPER SANDLER VIRTUAL OPHTHALMOLOGY INVESTOR SYMPOSIUM ON THURSDAY, JULY 9, 2026, AT 12:30 PM ET.

BELITE BIO TO PARTICIPATE IN THE PIPER SANDLER VIRTUAL OPHTHALMOLOGY INVESTOR SYMPOSIUM

SAN DIEGO, JULY 06, 2026 (GLOBE NEWSWIRE) -- BELITE BIO, INC (NASDAQ: BLTE) (BELITE BIO OR THE COMPANY), A CLINICAL-STAGE DRUG DEVELOPMENT COMPANY FOCUSED ON ADVANCING NOVEL THERAPEUTICS TARGETING DEGENERATIVE RETINAL DISEASES THAT HAVE SIGNIFICANT UNMET MEDICAL NEEDS, TODAY ANNOUNCED THAT BELITE DATA WILL BE PRESENTED AT THE 63RD ANNUAL SYMPOSIUM OF THE INTERNATIONAL SOCIETY FOR CLINICAL ELECTROPHYSIOLOGY OF VISION (ISCEV) BEING HELD ON JULY 6-11, 2026, IN SYDNEY, AUSTRALIA, AND THE AMERICAN SOCIETY OF RETINA SPECIALISTS (ASRS) 2026 ANNUAL MEETING BEING HELD ON JULY 15-18, 2026, IN MONTRAL, CANADA.

BELITE BIO ANNOUNCES ORAL PRESENTATIONS AT TWO UPCOMING MEDICAL CONFERENCES

SAN DIEGO, JUNE 12, 2026 (GLOBE NEWSWIRE) -- BELITE BIO, INC (NASDAQ: BLTE) (BELITE BIO OR THE COMPANY), A CLINICAL-STAGE DRUG DEVELOPMENT COMPANY FOCUSED ON ADVANCING NOVEL THERAPEUTICS TARGETING DEGENERATIVE RETINAL DISEASES THAT HAVE SIGNIFICANT UNMET MEDICAL NEEDS, TODAY ANNOUNCED THE COMPLETION OF ITS ROLLING SUBMISSION OF A NEW DRUG APPLICATION (NDA) TO THE U.S. FOOD AND DRUG ADMINISTRATION (FDA) FOR TINLAREBANT. TINLAREBANT IS AN INVESTIGATIONAL, ONCE-DAILY ORAL THERAPY FOR THE TREATMENT OF STARGARDT DISEASE TYPE 1 (STGD1), A RARE, INHERITED RETINAL DISEASE CAUSED BY MUTATIONS IN THE ABCA4 GENE THAT LEADS TO PROGRESSIVE AND IRREVERSIBLE VISION LOSS. STGD1 AFFECTS AN ESTIMATED 53,000 PEOPLE IN THE U.S. ALONE, AND THERE ARE CURRENTLY NO APPROVED TREATMENT OPTIONS FOR THE DISEASE.

BELITE BIO COMPLETES ROLLING SUBMISSION OF NEW DRUG APPLICATION TO U.S. FOOD AND DRUG ADMINISTRATION FOR TINLAREBANT FOR THE TREATMENT OF STARGARDT DISEASE TYPE 1

SAN DIEGO, JUNE 02, 2026 (GLOBE NEWSWIRE) -- BELITE BIO, INC (NASDAQ: BLTE) (BELITE BIO OR THE COMPANY), A CLINICAL-STAGE DRUG DEVELOPMENT COMPANY FOCUSED ON ADVANCING NOVEL THERAPEUTICS TARGETING DEGENERATIVE RETINAL DISEASES THAT HAVE SIGNIFICANT UNMET MEDICAL NEEDS, TODAY ANNOUNCED THAT THE COMPANY WILL PARTICIPATE IN A FIRESIDE CHAT AT THE GOLDMAN SACHS 47TH ANNUAL GLOBAL HEALTHCARE CONFERENCE ON MONDAY, JUNE 8, 2026 AT 4:00 PM ET. WEBCAST LINK INSTRUCTIONS WEBCASTS OF THE PRESENTATIONS CAN BE ACCESSED UNDER "EVENTS" IN THE INVESTOR RELATIONS SECTION OF THE BELITE BIO WEBSITE AT: HTTPS://INVESTORS.BELITEBIO.COM/PRESENTATIONS-EVENTS/EVENTS.

BELITE BIO TO PARTICIPATE IN THE GOLDMAN SACHS 47TH ANNUAL GLOBAL HEALTHCARE CONFERENCE

SAN DIEGO, MAY 20, 2026 (GLOBE NEWSWIRE) -- BELITE BIO, INC (NASDAQ: BLTE) (BELITE BIO OR THE COMPANY), A CLINICAL-STAGE DRUG DEVELOPMENT COMPANY FOCUSED ON ADVANCING NOVEL THERAPEUTICS TARGETING DEGENERATIVE RETINAL DISEASES THAT HAVE SIGNIFICANT UNMET MEDICAL NEEDS, TODAY ANNOUNCED ITS UNAUDITED FINANCIAL RESULTS FOR THE FIRST QUARTER ENDED MARCH31, 2026, AND PROVIDED A BUSINESS UPDATE.

BELITE BIO REPORTS UNAUDITED FIRST QUARTER 2026 FINANCIAL RESULTS AND PROVIDES A CORPORATE UPDATE

SAN DIEGO, MAY 18, 2026 (GLOBE NEWSWIRE) -- BELITE BIO, INC (NASDAQ: BLTE) (BELITE BIO OR THE COMPANY), A CLINICAL-STAGE DRUG DEVELOPMENT COMPANY FOCUSED ON ADVANCING NOVEL THERAPEUTICS TARGETING DEGENERATIVE RETINAL DISEASES THAT HAVE SIGNIFICANT UNMET MEDICAL NEEDS, TODAY ANNOUNCED THAT THE SWISS AGENCY FOR THERAPEUTIC PRODUCTS (SWISSMEDIC) HAS GRANTED TINLAREBANT, THE COMPANY'S LEAD PRODUCT CANDIDATE, ORPHAN DRUG STATUS (ODS) FOR THE TREATMENT OF STARGARDT DISEASE (STGD1), A RARE, INHERITED RETINAL DISORDER CAUSED BY MUTATIONS IN THE ABCA4 GENE.

BELITE BIO RECEIVES ORPHAN DRUG STATUS FOR TINLAREBANT IN STARGARDT DISEASE IN SWITZERLAND

SAN DIEGO, MAY 15, 2026 (GLOBE NEWSWIRE) -- BELITE BIO, INC. (NASDAQ: BLTE), (BELITE BIO OR THE COMPANY), A CLINICAL-STAGE BIOPHARMACEUTICAL DRUG DEVELOPMENT COMPANY FOCUSED ON ADVANCING NOVEL THERAPEUTICS TARGETING DEGENERATIVE RETINAL DISEASES THAT HAVE SIGNIFICANT UNMET MEDICAL NEEDS, TODAY ANNOUNCED THAT THE COMPANY WILL GIVE AN ORAL PRESENTATION AT THE 27TH FUNDUS DISEASE FORUM AND INTERNATIONAL RETINAL SYMPOSIUM(RETINA CHINA 2026) BEING HELD FROM MAY 21-23, 2026, IN NANJING, CHINA. THE PRESENTATION WILL COVER THE PREVIOUSLY DISCLOSED POSITIVE TOPLINE RESULTS FROM THE PHASE 3 DRAGON TRIAL,WHICH EVALUATED TINLAREBANT FOR THE TREATMENT OF STARGARDT DISEASE TYPE 1 (STGD1).

BELITE BIO ANNOUNCES ORAL PRESENTATION AT THE 27TH FUNDUS DISEASE FORUM AND INTERNATIONAL RETINAL SYMPOSIUM(RETINA CHINA 2026)

SAN DIEGO, MAY 13, 2026 (GLOBE NEWSWIRE) -- BELITE BIO, INC. (NASDAQ: BLTE), (BELITE BIO OR THE COMPANY), A CLINICAL-STAGE BIOPHARMACEUTICAL DRUG DEVELOPMENT COMPANY FOCUSED ON ADVANCING NOVEL THERAPEUTICS TARGETING DEGENERATIVE RETINAL DISEASES THAT HAVE SIGNIFICANT UNMET MEDICAL NEEDS, TODAY ANNOUNCED THAT IT WILL HOST A WEBCAST ON WEDNESDAY, MAY 20, 2026, AT 4:30 P.M. EASTERN TIME TO DISCUSS THE COMPANY'S FINANCIAL RESULTS AND PROVIDE A BUSINESS UPDATE FOR THE FIRST QUARTER ENDED MARCH 31, 2026.

Belite Bio, Inc

BLTE

Price

Financial Reports

No items found.

Press Releases

Belite Bio, Inc

BLTE.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financial Reports

No items found.

Press Releases

BLTE